Search clinical trials for: SCH 530348

Total 2349 results

Merck Sharp & Dohme LLC
Duke Clinical Research Institute

Terminated

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Myocardial Infarction | Myocardial Ischemia | Atherosclerosis
Merck Sharp & Dohme LLC

Completed

Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Coronary Disease | Arterial Obstructive Diseases
Merck Sharp & Dohme LLC

Completed

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

Acute Coronary Syndrome
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Hepatitis C, Chronic
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Clinical Study of SPH3348 Tablets, a c-Met Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (SPRINT-2)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

HIV Infections | Hepatitis C | HCV Infection
Merck Sharp & Dohme LLC

Terminated

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
Merck Sharp & Dohme LLC

Withdrawn

A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)

Hepatitis C
Procter and Gamble

Completed

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Osteoarthritis, Knee

Hungary, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Hepatitis C, Chronic
University Hospitals Cleveland Medical Center
University of Pittsburgh; The Cleveland Clinic; Duke University; Case Western Reserve... and other collaborators

Recruiting

Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse (PREMIER)

Uterine Prolapse

United States
Merck Sharp & Dohme LLC

Completed

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Bladder Neoplasms
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Completed

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Chronic Hepatitis C Genotype 1
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
ALK-Abelló A/S

Completed

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Allergy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

Hepatitis C, Chronic

Canada
Merck Sharp & Dohme LLC

Withdrawn

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Asthma
M.D. Anderson Cancer Center
Schering-Plough

Withdrawn

SCH-900105 in Recurrent Glioblastoma

Glioblastoma
ALK-Abelló A/S

Completed

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

Conjunctivitis | Rhinitis Allergic
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Parkinson Disease
Merck Sharp & Dohme LLC

Terminated

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors | Leukemia, Lymphocytic, Chronic. B-Cell
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Obesity | Overweight | Body Weight
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Asthma
Merck Sharp & Dohme LLC

Terminated

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Completed

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) (GO-MORE)

Arthritis, Rheumatoid
Merck Sharp & Dohme LLC

Completed

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Psychosis
ALK-Abelló A/S

Completed

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
Merck Sharp & Dohme LLC

Completed

Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)

Cough
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

HIV Infections

United States
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Conjunctivitis | Rhinitis; Allergic, With Asthma
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States
UConn Health

Active, not recruiting

Sickle Cell Hemoglobinopathies and Bone Health

Sickle Cell Disease | Sickle Cell Trait

United States
Merck Sharp & Dohme LLC

Completed

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Alzheimer's Disease

3

Subscribe